|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Giant cavernous liver hemangiomas: is it the time to change the size categories?显示文摘BACKGROUND: Four different sizes(4, 5, 8 and 10 cm in diameter) can be found in the literature to categorize a liver hemangioma as giant. The present review aims to clarify the appropriateness of the size category 'giant' for liver hemangioma.DATA SOURCES: We reviewed the reports on the categorization of hemangioma published between 1970 and 2014. The number of hemangiomas, size criteria, mean and range of hemangioma sizes, and number of asymptomatic and symptomatic patients were investigated in patients aged over 18 years. Liver hemangiomas were divided into four groups: <5.0 cm, 5.0-9.9 cm, 10.0-14.9 cm and ≥15.0 cm in diameter. Inclusion criteria were noted in 34 articles involving 1972(43.0%) hemangiomas(>4.0 cm).RESULTS: The patients were divided into the following groups: 154 patients(30.0%) with hemangiomas less than 5.0 cm in diameter(small), 182(35.5%) between 5.0 cm and 9.9 cm(large), 75(14.6%) between 10.0 and 14.9 cm(giant), and 102(19.9%) more than 15.0 cm(enormous). There were 786(39.9%) asymptomatic patients and 791(40.1%) symptomatic patients. Indications for surgery related to symptoms were reported in only 75(3.8%) patients. Operations including 137 non-anatomical resection(12.9%) and 469 enucleation(44.1%) were unclearly related to size and symptoms.CONCLUSIONS: The term 'giant' seems to be justified for liver hemangiomas with a diameter of 10 cm. Hemangiomas categorized as 'giant' are not indicated for surgery. Surgery should be performed only when other symptoms are apparent. | isidoro di carlo renol koshy saif al mudares annalisa ardiri gaetano bertino adriana toro | 2016 | Hepatobiliary & Pancreatic Diseases International2016，15，1： | 22 |
| 2 | Chronic hepatitis C:This and the new era of treatment显示文摘Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This occurred for the availability of direct-acting antiviral agents that allow to reach sustained virologic response in approximately 90% of cases. In the near future further progress will be achieved with the use of pan-genotypic drugs with high efficacy but without side effects. | Gaetano Bertino Annalisa Ardiri Maria Proiti Giuseppe Rigano Evelise Frazzetto Shirin Demma MariaIrene Ruggeri Laura Scuderi Giulia Malaguarnera Nicoletta Bertino Venerando Rapisarda Isidoro Di Carlo Adriana Toro Federico Salomone Mariano Malaguarnera Emanuele Bertino Michele Malaguarnera | 2016 | World Journal of Hepatology2016，8，2： | 10 |
| 3 | Hepatocellular carcinoma and the risk of occupational exposure显示文摘Hepatocellular carcinoma(HCC)is the most common type of liver cancer.The main risk factors for HCC are alcoholism,hepatitis B virus,hepatitis C virus,nonalcoholic steatohepatitis,obesity,type 2 diabetes,cirrhosis,aflatoxin,hemochromatosis,Wilson’s disease and hemophilia.Occupational exposure to chemicals is another risk factor for HCC.Often the relationship between occupational risk and HCC is unclear and the reports are fragmented and inconsistent.This review aims to summarize the current knowledge regarding the association of infective and non-infective occupational risk exposure and HCC in order to encourage further research and draw attention to this global occupational public health problem. | Venerando Rapisarda Carla Loreto Michele Malaguarnera Annalisa Ardiri Maria Proiti Giuseppe Rigano Evelise Frazzetto Maria Irene Ruggeri Giulia Malaguarnera Nicoletta Bertino Mariano Malaguarnera Vito Emanuele Catania Isidoro Di Carlo Adriana Toro Emanuele Bertino Dario Mangano Gaetano Bertino | 2016 | World Journal of Hepatology2016，8，13： | 5 |
| 4 | Hepatocellualar Carcinoma Serum Markers显示文摘 | Gaetano Bertino Annalisa Ardiri Michele Malaguarnera Giulia Malaguarnera Nicoletta Bertino Giuseppe Stefano Calvagno | 2012 | Seminars in Oncology2012，，4： | 3 |
| 5 | Systemic therapies in hepatocellular carcinoma: present and future显示文摘 | Gaetano Bertino Isidoro Di Carlo Annalisa Ardiri Giuseppe Stefano Calvagno Shirin Demma Giulia Malaguarnera Nicoletta Bertino Mariano Malaguarnera Adriana Toro Michele Malaguarnera | 2013 | Future Oncol2013，，10： | 3 |
| 6 | Hepatocelluar carcinoma serum markers 显示文摘 | Bertino G Ardiri A Malaguarnera M | 2012 | Semin Oncol2012，39，4： | 1 |
| 7 | Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies显示文摘 | Bertino G Demma S Ardiri A | 2014 | Biol Med Res Int2014，2014，6： | 1 |
| 8 | MiR-424 and miR-155 dereg- ulated expression in cytogenetically normal acute myeloid leuke-mia: correlation with NPM1 and FLT3 mutation status显示文摘 | Faraoni I Laterza S Ardiri D | 2012 | J He- matology Oncology2012，5，1： | 1 |
| 9 | Hepatocellualar car-cinoma serum markers显示文摘 | Bertino G Ardiri A Malaguamera M | 2012 | Semin Oncol2012，39，4： | 1 |
| 10 | Hepatocellualar carcinoma serum markers显示文摘 | Bertino G Ardiri A Malaguamera M | | 0，，04： | 1 |
| 11 | A study about mechanismsof des-gamma-carboxy prothrombin's production in hepatocellularcarcinoma显示文摘 | Bertino G Ardiri AM Boemi PM | 2008 | Panminerva Med2008，50，： | 1 |
| 12 | MiR-424 andmiR-155 deregulated expression in cytogenetically normalacute myeloid leukaemia : correlation with NPM1 andFLT3 mutation status 显示文摘 | Faraoni I Laterza S Ardiri D | 2012 | J Hematol Oncol2012，5，26： | 1 |
| 13 | Prognostic and diag-nostic value of des -7 -carboxy prothrombin in liver cancer 显示文摘 | Bertino G Ardiri AM Calvagno GS | 2010 | Drug News and Perspectives2010，23，： | 1 |
| 14 | Hepatocellualar carci- noma serum markers显示文摘 | Bertino G Ardiri A Malaguarnera M | 2012 | Semin Oncol2012，39，： | 1 |
| 15 | Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies显示文摘 | Gaetano Bertino Shirin Demma Annalisa Ardiri Maria Proiti Salvatore Gruttadauria Adriana Toro Giulia Malaguarnera Nicoletta Bertino Michele Malaguarnera Mariano Malaguarnera Isidoro Di Carlo Jingmin Zhao | 2014 | BioMed Research International2014，，： | 1 |
| 16 | Hepatocellualar carci noma serum markers显示文摘 | Bertino G Ardiri A Malaguarnera M | 2012 | Semin Oncol2012，39，41： | 1 |
| 17 | Effect of pre- and post- treatment ct -fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study显示文摘 | Toro A Ardiri A Mannino M | 2014 | BMC Surg2014，，14： | 1 |
| 18 | Rare Benign Tumors of the Liver: Still Rare?显示文摘 | Gaetano Bertino Annalisa Ardiri Shirin Demma Stefano GiuseppeCalvagno Adriana Toro Elisa Basile Davide Campagna Giorgia Ferraro Evelise Frazzetto Maria Proiti Giulia Malaguarnera Nicoletta Bertino Mariano Malaguarnera Michele Malaguarnera Maria Domenica A | 2014 | Journal of Gastrointestinal Cancer2014，，2： | 1 |
| 19 | Hepatocel-lualar carcinoma serum markers显示文摘 | Bertino G Ardiri A Malaguarnera M | | 0，，04： | 1 |
| 20 | Hepatocellualar carcinoma serum markers显示文摘 | Bertino G Ardiri A Malaguamera M Malaguarnera G Bertino N Calvagno GS | 2012 | Semin Oncol2012，39，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员